A researcher investigates fever reduction in mice using a novel drug. If this drug inhibits phospholipase A2 (PLA2) activity in hypothalamic cells, which consequence follows?

💡 Explanation

PLA2 inhibition reduces arachidonic acid release, a precursor for prostaglandin synthesis. Because prostaglandin E2 (PGE2) is a key mediator of fever in the hypothalamus, its synthesis decreases. Therefore, the drug reduces fever by limiting PGE2 production rather than increasing inflammation via cytokine production.

• If a patient has a genetic defect causing continuously elevated cytosolic phospholipase A2 (cPLA2) activity, which consequence is most likely within inflammatory cells?
• Why does chronic inflammation persist even when initial triggers subside, specifically concerning the prostaglandin pathway?
• If a researcher isolates skeletal muscle fibers and introduces a non-hydrolyzable ATP analog during a contraction experiment, which consequence follows?
• Which signal delay results from hypomyelination during development?
• Why does age-related vascular stiffening increase systolic blood pressure more than diastolic blood pressure?
• If a patient experiences a severe asthma exacerbation triggered by histamine release from mast cells, which consequence follows from administering a beta-2 agonist inhaler?